Please use this identifier to cite or link to this item:
https://doi.org/10.1159/000087272
Title: | Treatment of chronic hepatitis C in patients with end-stage renal disease and hemophilia the Singapore experience | Authors: | Chow, WC Tien, SL Tan, CK Lui, HF Vathsala, A Ng, HS |
Keywords: | Science & Technology Life Sciences & Biomedicine Virology hemophilia hepatitis C virus interferon renal failure thyroid dysfunction HEMODIALYSIS-PATIENTS DIALYSIS PATIENTS RIBAVIRIN THERAPY INTERFERON-ALPHA VIRUS-INFECTION MONOTHERAPY TRIAL |
Issue Date: | 1-Jan-2005 | Publisher: | KARGER | Citation: | Chow, WC, Tien, SL, Tan, CK, Lui, HF, Vathsala, A, Ng, HS (2005-01-01). Treatment of chronic hepatitis C in patients with end-stage renal disease and hemophilia the Singapore experience. INTERVIROLOGY 49 (1-2) : 107-111. ScholarBank@NUS Repository. https://doi.org/10.1159/000087272 | Abstract: | Objective: The aim of this study was to determine the response to treatment with interferon-alpha (IFN-α) in patients with chronic hepatitis C who had end-stage renal disease (ESRD) or hemophilia in Singapore. Methods: Treatment-naive hepatitis patients with ESRD or hemophilia were given IFN-α2a 3 million units three times per week for 12 months in an open-label study. Hepatitis C virus RNA was determined before treatment, at the end of treatment and 6 months thereafter. Regular clinical examinations including blood counts and biochemistry were carried out during and after the treatment. Results: Nine consecutive patients with ESRD (8 men and 1 woman) and 6 consecutive male patients with hemophilia, with a mean age of 43 and 40 years, received treatment. Patients in both groups were predominantly infected with hepatitis C virus genotype 1 and had significant cytopenia affecting all three cell lines during the treatment; only 1 patient developed serious neutropenia, temporarily demanding a reduction of his IFN dose. Biochemical and virological responses at the end of treatment were accomplished by 8 of the 9 (89%) patients with ESRD and 4 of the 6 (67%) patients with hemophilia; however, 1 patient with ESRD and 2 with hemophilia relapsed after the treatment. Four of the 7 patients with ESRD who had sustained virological response underwent successful kidney transplantation later on. Conclusion: Monotherapy with IFN-α for 12 months is safe for treatment of the patients with chronic hepatitis C who had ESRD or those with hemophilia. A higher sustained virological response rate was observed in patients with ESRD than in those with hemophilia (78 vs. 33%). Copyright © 2006 S. Karger AG. | Source Title: | INTERVIROLOGY | URI: | https://scholarbank.nus.edu.sg/handle/10635/229817 | ISSN: | 03005526 14230100 |
DOI: | 10.1159/000087272 |
Appears in Collections: | Elements Staff Publications |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Treatment of HepC.pdf | 66.64 kB | Adobe PDF | CLOSED | Published |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.